| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | OPGN | Common Stock | 0 | 25 Mar 2024 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | OPGN | Series E Convertible Preferred Stock | 25 Mar 2024 | Common Stock | 4,800,000 | Direct | F2, F3, F4 |
| Id | Content |
|---|---|
| F1 | No shares of Common Stock are beneficially owned. |
| F2 | On March 25, 2024, David E. Lazar (the "Reporting Person") and OpGen, Inc. (the "Company"), entered into a securies purchase agreement pursuant to which the Reporting Person will acquire an aggregate of 3,000,000 shares of the Company's Series E Convertible Preferred Stock (the "Series E Preferred Stock") at a price of $1.00 per share. Each share of Series E Preferred Stock is convertible into 24 shares of the Company's Common Stock at any time, subject to certain ownership limitations. The initial closing took place on March 25, 2024, whereby the Reporting Person acquired 200,000 shares of Series E Preferred Stock for a total purchase price of $200,000. The Reporting Person will acquire additional shares of Series E Preferred Stock at subsequent closings. |
| F3 | The Series E Preferred Stock is perpetual and therefore has no expiration date. |
| F4 | The shares of Series E Preferred Stock are convertible at the option of the Reporting Person for no additional consideration. |